Adaptimmune Therapeutics 2022 Annual Report 10-K

Adaptimmune Therapeutics plc's Form 10-K annual report for the fiscal year ended December 31, 2022. The company is a biopharmaceutical firm developing SPEAR cell therapies for oncology indications, with headquarters in Abingdon, Oxfordshire, United Kingdom and U.S. listing on Nasdaq under ticker ADAP.